GSK initiate Phase I trial of Muscarinic M1 antagonist GSK1034702 « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
September 2008

M T W T F S S

« Aug Oct »

1 2 3 4 5 6 7

8 9 10 11 12 13 14

15 16 17 18 19 20 21

22 23 24 25 26 27 28

29 30

GSK initiate Phase I trial of Muscarinic M1 antagonist GSK1034702

Posted on September 2, 2008 by crimsoncanary

GSK have initiated a Phase I trial of Muscarinic M1 antagonist GSK1034702

Filed under: gpcr | Tagged: antagonist, GSK, GSK1034702, M1, Muscarinic, Muscarinic M1

« Pain Therapeutics and King present remoxy Phase III data Oxford BioMedicas gene therapy ProSavin effective in parkinsons »

Leave a Reply